Cavinton, Ampoules 25mg, 5ml, 10pcs

Composition

>

1 ml. contains vinpocetine 5 mg.

Auxiliary substances:

ascorbic acid,

sodium disulfite,

tartaric acid,

benzyl alcohol,

sorbitol,

d/i water.

Pharmacological action

A drug that improves cerebral circulation and brain metabolism. Improves brain metabolism by increasing the consumption of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; increases the transport of glucose to the brain, through the BBB; transfers the process of glucose breakdown to an energy-efficient, aerobic pathway; selectively blocks Ca2+ – dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of ATP in brain tissues; increases the exchange of norepinephrine and serotonin in the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of red blood cells and blocks the utilization of adenosine by red blood cells; promotes increased oxygen release by red blood cells. Enhances the neuroprotective effect of adenosine. Increases cerebral blood flow; reduces resistance of cerebral vessels without significant changes in the parameters of systemic circulation (blood pressure, minute volume, heart rate, OPSS). It does not have the effect of” stealing”, increases blood supply, primarily in ischemic areas of the brain with low perfusion.

Indications

reducing the severity of neurological and psychiatric symptoms in various forms of circulatory failure of the brain (ischemic stroke, the recovery stage of hemorrhagic stroke, the effects of a stroke;transient ischemic attack;vascular dementia;vertebrobasilar insufficiency;atherosclerosis of cerebral vessels;post-traumatic and hypertensive encephalopathy);chronic disease of the choroid and retina of the eye (e. g., thrombosis /occlusion/ Central artery or vein of the retina);for the treatment of hearing loss perceptual type, Meniere’s disease, idiopathic tinnitus.

Use during pregnancy and lactation

The drug is contraindicated during pregnancy and lactation.

Contraindications

• Acute phase of hemorrhagic stroke;
• Severe CHD;
• Severe arrhythmias.
• Under 18 years of age (due to insufficient data).
• Known hypersensitivity to vinpocetine.

Side effects

From the cardiovascular system:  it is possible to increase the manifestations of existing arrhythmia.

From the digestive system:  nausea, heartburn, dry mouth.

From the central nervous system:  headache, dizziness, sleep disturbance, weakness.

Allergic reactions:  skin rash, urticaria.

Skin reactions:  hyperemia of the skin.

Interaction

When used concomitantly, there is no interaction with beta-blockers (chloranolol, pindolol), clopamide, glibenclamide, digoxin, acenocoumarol or hydrochlorothiazide. In rare cases, concomitant use with alpha-methyldopa is accompanied by a slight increase in the antihypertensive effect, with the use of such a combination, regular blood pressure monitoring is necessary. Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when prescribing concomitantly with central-acting drugs and antiarrhythmics. Pharmaceutical interaction The concentrate for preparing an infusion solution and heparin are chemically incompatible, so it is forbidden to introduce them in the same infusion mixture, but you can simultaneously treat with anticoagulants and vinpocetine. The infusion solution preparation concentrate is incompatible with infusion solutions containing the amino acid, so they cannot be used for dilution of Cavinton.

How to take, course of use and dosage

The drug is intended for intravenous drip infusion. Enter slowly, the infusion rate should not exceed 80 drops/min. It is

forbidden to enter IV and IV without dilution.

To prepare the infusion, you can use saline or dextrose-containing solutions (Salsol, Ringer, Rindex, Reomacrodex). Infusion solution with Cavinton should be used in the first 3 hours after preparation.

The usual initial daily dose is 20-25 mg in 500 ml of infusion solution. Depending on the tolerance, the dose can be increased to no more than 1 mg/kg/day within 2-3 days. The average duration of treatment is 10-14 days.

The average daily dose for a body weight of 70 kg is 50 mg (in 500 ml of infusion solution).

No dose adjustment is required for liver and kidney diseases.

At the end of the IV therapy course, it is recommended to continue treatment with Cavinton Forte tablets (1 tab. 3 times/day). or Cavinton (2 tablets 3 times/day).

Overdose

Currently, data on overdose of Cavinton are limited.

Treatment: performing symptomatic therapy.

Special instructions

The presence of prolonged QT syndrome and the use of drugs that cause prolongation of the QT interval requires periodic monitoring of the ECG. Cavinton infusion solution contains sorbitol (160 mg / 2 ml), so if you have diabetes, you should periodically monitor your blood glucose level. In case of fructose intolerance or fructose 1,6-diphosphatase deficiency, the use of vinpocetine should be avoided. Effect on the ability to drive motor vehicles and operate mechanicsmidays on the effect of vinpocetine on the ability to drive a car and work mechanisms are not available.

Form of production

Concentrate for preparing an infusion solution is colorless or slightly greenish, transparent.

Storage conditions

In a dark place, at a temperature of 15-30 °C

Shelf life

5 years

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution